Literature DB >> 25762769

The Resistant-Population Cutoff (RCOFF): a New Concept for Improved Characterization of Antimicrobial Susceptibility Patterns of Non-Wild-Type Bacterial Populations.

Giorgia Valsesia1, Michael Hombach1, Florian P Maurer1, Patrice Courvalin2, Malgorzata Roos3, Erik C Böttger4.   

Abstract

This study aimed to determine resistant-population cutoffs (RCOFFs) to allow for improved characterization of antimicrobial susceptibility patterns in bacterial populations. RCOFFs can complement epidemiological cutoff (ECOFF)-based settings of clinical breakpoints (CBPs) by systematically describing the correlation between non-wild-type and wild-type populations. We illustrate this concept by describing three paradigmatic examples of wild-type and non-wild-type Escherichia coli populations from our clinical strain database of disk diffusion diameters. The statistical determination of RCOFFs and ECOFFs and their standardized applications in antimicrobial susceptibility testing (AST) facilitates the assignment of isolates to wild-type or non-wild-type populations. This should improve the correlation of in vitro AST data and distinct antibiotic resistance mechanisms with clinical outcome facilitating the setting and validation of CBPs.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25762769      PMCID： PMC4432042          DOI： 10.1128/JCM.03505-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  28 in total

Review 1.  Bacterial genomics in infectious disease and the clinical pathology laboratory.

Authors:  Randall J Olsen; S Wesley Long; James M Musser
Journal:  Arch Pathol Lab Med       Date:  2012-03-22       Impact factor: 5.534

Review 2.  The ABCD's of β-lactamase nomenclature.

Authors:  Karen Bush
Journal:  J Infect Chemother       Date:  2013-07-05       Impact factor: 2.211

3.  Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories.

Authors:  E Matuschek; D F J Brown; G Kahlmeter
Journal:  Clin Microbiol Infect       Date:  2013-10-17       Impact factor: 8.067

4.  Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.

Authors:  F Docobo-Pérez; L López-Cerero; R López-Rojas; P Egea; J Domínguez-Herrera; J Rodríguez-Baño; A Pascual; J Pachón
Journal:  Antimicrob Agents Chemother       Date:  2013-02-25       Impact factor: 5.191

Review 5.  Bacterial resistance mechanism: what proteomics can elucidate.

Authors:  Thais Bergamin Lima; Michelle Flaviane Soares Pinto; Suzana Meira Ribeiro; Loiane Alves de Lima; Juliana Cançado Viana; Nelson Gomes Júnior; Elizabete de Souza Cândido; Simoni Campos Dias; Octávio Luiz Franco
Journal:  FASEB J       Date:  2013-01-24       Impact factor: 5.191

6.  Evaluation of a diagnostic flow chart for detection and confirmation of extended spectrum β-lactamases (ESBL) in Enterobacteriaceae.

Authors:  S Polsfuss; G V Bloemberg; J Giger; V Meyer; E C Böttger; M Hombach
Journal:  Clin Microbiol Infect       Date:  2012-01-20       Impact factor: 8.067

7.  Integrating forecast probabilities in antibiograms: a way to guide antimicrobial prescriptions more reliably?

Authors:  Florian P Maurer; Patrice Courvalin; Erik C Böttger; Michael Hombach
Journal:  J Clin Microbiol       Date:  2014-08-06       Impact factor: 5.948

8.  Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamase: a case-control study of risk factors and outcomes.

Authors:  Pak-Leung Ho; Wai-Ming Chan; Kenneth W T Tsang; Samson S Y Wong; Karl Young
Journal:  Scand J Infect Dis       Date:  2002

9.  A statistical approach for determination of disk diffusion-based cutoff values for systematic characterization of wild-type and non-wild-type bacterial populations in antimicrobial susceptibility testing.

Authors:  Giorgia Valsesia; Malgorzata Roos; Erik C Böttger; Michael Hombach
Journal:  J Clin Microbiol       Date:  2015-03-11       Impact factor: 5.948

Review 10.  Modern clinical microbiology: new challenges and solutions.

Authors:  Pierre-Edouard Fournier; Michel Drancourt; Philippe Colson; Jean-Marc Rolain; Bernard La Scola; Didier Raoult
Journal:  Nat Rev Microbiol       Date:  2013-08       Impact factor: 60.633
View more
  4 in total

1.  On the Consequences of Poorly Defined Breakpoints for Rifampin Susceptibility Testing of Mycobacterium tuberculosis Complex.

Authors:  Claudio U Köser; Sophia B Georghiou; Thomas Schön; Max Salfinger
Journal:  J Clin Microbiol       Date:  2021-03-19       Impact factor: 5.948

2.  A statistical approach for determination of disk diffusion-based cutoff values for systematic characterization of wild-type and non-wild-type bacterial populations in antimicrobial susceptibility testing.

Authors:  Giorgia Valsesia; Malgorzata Roos; Erik C Böttger; Michael Hombach
Journal:  J Clin Microbiol       Date:  2015-03-11       Impact factor: 5.948

3.  MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era.

Authors:  Patrick Beckert; Elisabeth Sanchez-Padilla; Matthias Merker; Viola Dreyer; Thomas A Kohl; Christian Utpatel; Claudio U Köser; Ivan Barilar; Nazir Ismail; Shaheed Vally Omar; Marisa Klopper; Robin M Warren; Harald Hoffmann; Gugu Maphalala; Elisa Ardizzoni; Bouke C de Jong; Bernhard Kerschberger; Birgit Schramm; Sönke Andres; Katharina Kranzer; Florian P Maurer; Maryline Bonnet; Stefan Niemann
Journal:  Genome Med       Date:  2020-11-25       Impact factor: 11.117

4.  Markedly decreasing azithromycin susceptibility of Neisseria gonorrhoeae, Germany, 2014 to 2021.

Authors:  Regina Selb; Susanne Buder; Sandra Dudareva; Thalea Tamminga; Viviane Bremer; Sebastian Banhart; Dagmar Heuer; Klaus Jansen
Journal:  Euro Surveill       Date:  2021-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.